Resverlogix Corp.

(RVX:APH)

By |

Profile

Resverlogix Corp clinical stage biotechnology company. Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Contact Information

Website: www.resverlogix.com
Email: sarah@resverlogix.com
Main Phone: +1 403 254-9252
Address: 4820 Richard Road SW
Address 2: Suite 300
State: AB
City / Town: Calgary
Country: CAN
Postal Code: T3E 6L1

Issuer Information

Exchange: TSX
CEO: Donald McCaffrey
Employees: 30
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange TSX
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 8.55 8.55 8.55 8.55
Low Target Price Estimate 6.29 6.29 6.29 6.29
Mean Target Price Estimate 7.42 7.42 7.42 7.42
Standard Deviation 1.6 1.6 1.6 1.6
Date of Most Recent Estimate 04/12/18 04/12/18 04/12/18 04/12/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1